Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes for the treatment of patients with EBV-positive relapsed Hodgkin's disease

Blood

Volumn 91, Issue 8, 1998, Pages 2925-2934

  Roskrow, Marie A ^b   Suzuki, Nobuhiro ^b   Gan, Yan Jun ^b   Sixbey, John W ^b   Ng, Catherine Y C ^b   Kimbrough, Sarah ^b   Hudson, Melissa ^b   Brenner, Malcolm K ^b   Heslop, Helen E ^b   Rooney, Cliona M ^a  

^a TEXAS CHILDREN S HOSPITAL   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY TEST; EPSTEIN BARR VIRUS; HODGKIN DISEASE; HUMAN; HUMAN CELL; PHENOTYPE; PRIORITY JOURNAL; RELAPSE; REMISSION;

EID: 0032523173     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v91.8.2925.2925_2925_2934     Document Type: Article

References (39)

1. Weiss LM, Movahed LA, Warnke RA, Sklar J: Detection of Epstein-Barr viral genomes in Reed-Sternberg cells of Hodgkin's disease. N Engl J Med 320:502, 1989
2. Chang KL, Albujar PF, Chen YY, Johnson RM, Weiss LM: High prevalence of Epstein-Barr virus in the Reed-Sternberg cells of Hodgkin's disease occurring in Peru. Blood 81:496, 1993
3. Weinreb M, Day PJ, Niggli F, Green EK, Nyong'o AO, Othieno-Abinya NA, Riyat MS, Raafat F, Mann JR: The consistent association between Epstein-Barr virus and Hodgkin's disease in children in Kenya. Blood 87:3828, 1996
4. Raab-Traub N: Epstein-Barr virus and nasopharyngeal carcinoma. Semin Cancer Biol 3:297, 1992
5. Magrath I, Jain V, Bhatia K: Epstein-Barr virus and Burkitt's lymphoma. Semin Cancer Biol 3:285, 1992
6. Thomas JA, Allday M, Crawford DH: Epstein-Barr virus-associated lymphoproliferative disorders in immunocompromised individuals. Adv Cancer Res 57:329, 1991
7. Rooney CM, Smith CA, Ng C, Loftin SK, Li C, Krance RA, Brenner MK, Heslop HE: Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr virus-related lymphoproliferation. Lancet 345:9, 1995
8. Heslop HE, Ng CYC, Li C, Smith CA, Loftin SK, Krance RA, Brenner MK, Rooney CM: Long-term restoration of immunity against Epstein-Barr virus infection by adoptive transfer of gene-modified virus-specific T lymphocytes. Nat Med 2:551, 1996
9. Beaty O, Hudson MM, Greenwald C, Luo X, Fang L, Wilimas JA, Thompson EI, Kun LE, Pratt CB: Subsequent malignancies in children and adolescents after treatment for Hodgkin's disease. J Clin Oncol 13:603, 1995
10. Slivnick DJ, Ellis TM, Nawrocki JF, Fisher RI: The impact of Hodgkin's disease on the immune system. Semin Oncol 17:673, 1990
11. Renner C, Ohnesorge S, Held G, Bauer S, Jung W, Pfitzenmeier JP, Pfreundschuh M: T cells from patients with Hodgkin's disease have a defective T-cell receptor zeta chain expression that is reversible by T-cell stimulation with CD3 and CD28. Blood 88:236, 1996
12. Herbst H, Foss H, Samol J, Araujo I, Klotzbach H, Krause H, Agathanggelou A, Niedobitek G, Stein H: Frequent expression of interleukin-10 by Epstein-Barr virus-harboring tumor cells of Hodgkin's disease. Blood 87:2918, 1996
13. Strand S, Hofmann WJ, Hug H, Muller M, Otto G, Strand D, Mariani SM, Stremmel W, Krammer PH, Gale PR: Lymphocyte apoptosis induced by CD95 (APO-1/fas) ligand-expressing tumor cells-A mechanism of immune evasion? Nat Med 2:1361, 1996
14. Gimmi CD, Morrison BW, Mainprice BA, Gribben JG, Boussiotis VA, Freeman GJ, Lee Park SY, Watanabe M, Gong JL, Hayes DF, Kufe DW, Nadler LM: Breast cancer-associated antigen, DF3/MUC1, induces apoptosis of activated human T cells. Nat Med 2:1367, 1996
15. Herbst H, Dallenback F, Hummel M, Niedobitek G, Pileri S, Nuller-Lantzsch N, Stein H: Epstein-Barr virus latent membrane protein expression in Hodgkin and Reed-Sternberg cells. Proc Natl Acad Sci USA 88:4766, 1991
16. Khanna R, Burrows SR, Kurilla MG, Jacob CA, Misko IS, Sculley TB, Kieff E, Moss DJ: Localization of Epstein-Barr virus cytotoxic T cell epitopes using recombinant vaccinia: Implications for vaccine development. J Exp Med 176:169, 1992
17. Smith CA, Ng CYC, Heslop HE, Holladay MS, Richardson S, Turner EV, Loftin SK, Li C, Brenner MK, Rooney CM: Production of genetically modified EBV-specific cytotoxic T cells for adoptive transfer to patients at high risk of EBV-associated lymphoproliferative disease. J Hematother 4:73, 1995
18. MacMahon EME, Glass JD, Hayward SD, Mann RB, Becker PS, Charache P, McArthur JC, Ambinder RF: Epstein-Barr virus in AIDS-related primary central nervous system lymphoma. Lancet 338:969, 1991
19. Miller G, Lipman M: Release of infectious Epstein-Barr virus by transformed marmoset leukocytes. Proc Natl Acad Sci USA 70:190, 1973
20. Rickinson AB, Rowe M, Hart I, Yao QY, Henderson LE, Rabin H, Epstein MA: T cell-mediated regression of "spontaneous" and of Epstein-Barr virus-induced B cell transformation in vitro: Studies with cyclosporin A. Cell Immunol 87:646, 1984
21. Riddell SR, Greenberg PD: The use of anti-CD3 and anti-CD28 monoclonal antibodies to clone and expand antigen specific T cells. J Immunol Methods 128:189, 1990
22. Murray RJ, Kurilla MG, Brooks JM, Thomas WA, Rowe M, Kieff E, Rickinson AB: Identification of target antigens for the human cytotoxic T cell response to Epstein-Barr virus (EBV): Implications for the immune control of EBV-positive malignancies. J Exp Med 176:157, 1992
23. Smith CA, Ng CYC, Loftin SK, Li C, Heslop HE, Brenner MK, Rooney CM: Adoptive immunotherapy for Epstein-Barr virus-related lymphoma. Leuk Lymphoma 23:213, 1996
24. Bourgault I, Gomez A, Gomard E, Levy JP: Limiting-dilution analysis of the HLA restriction of anti-Epstein-Barr virus-specific cytolytic T lymphocytes. Clin Exp Immunol 84:501, 1991
25. Rooney CM, Loftin SK, Holladay MS, Brenner MK, Krance RA, Heslop HE: Early identification of Epstein-Barr virus-associated post-transplant lymphoproliferative disease. Br J Haematol 89:98, 1995
26. Frisan T, Sjoberg J, Dolcetti R, Boiocchi M, De Re V, Carbone A, Brautbar C, Battat S, Biberfeld P, Eckman M, Ost A, Christensson B, Sundstrom C, Bjorkholm M, Pisa P, Masucci MG: Local suppression of Epstein-Barr virus (EBV)-specific cytotoxicity in biopsies of EBV-positive Hodgkin's disease. Blood 86:1493, 1995
27. Sing AP, Ambinder RF, Hong DJ, Jensen M, Batten W, Petersdorf E, Greenberg PD: Isolation of Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes that lyse Reed-Sternberg cells: Implications for immune-mediated therapy of EBV Hodgkin's disease. Blood 89:1978, 1997
28. Wange RL, Samelson LE: Complex complexes: Signaling at the TCR. Immunity 5:197, 1996
29. Rubin B, Martin EPG, Arnaud J, Delsol G, Plesner T, Ratsimbazafy A, Llobera R, Holm B, Mariame B: Expression and signal transduction of T-cell antigen receptor (TCR)/CD3 complexes on fresh or in vitro expanded T lymphocytes from patients with Hodgkin's disease and non-Hodgkin's lymphomas. Scand J Immunol 45:715, 1997
30. Qu L, Rowe DT: Epstein-Barr virus latent gene expression in uncultured peripheral blood lymphocytes. J Virol 66:3715, 1992
31. Miyashita EM, Yang B, Babcock GJ, Thorley-Lawson DA: Identification of the site of Epstein-Barr virus persistence in vivo as a resting B cell. J Virol 71:4882, 1997
32. Rickinson AB, Kieff E: Epstein-Barr virus, in Fields BN, Knipe DM, Howley PM (eds): Fields Virology. Philadelphia, PA, Lipincott-Raven, 1996, p 2397
33. Levitskaya J, Coram M, Levitsky V, Imreh S, Steigerwald-Mullen PM, Klein G, Kurilla MG, Masucci MG: Inhibition of antigen processing by the internal repeat region of the Epstein-Barr virus nuclear antigen-1. Nature 375:685, 1995
34. Lee SP, Thomas WA, Murray RJ, Khanin F, Kaur S, Young LS, Rowe M, Kurilla M, Rickinson AB: HLA A2.1-restricted cytotoxic T cells recognizing a range of Epstein-Barr virus isolates through a defined epitope in latent membrane protein LMP2. J Virol 67:7428, 1993
35. Knecht H, Bachmann E, Joske JL: Molecular analysis of the LMP (latent membrane protein) in Hodgkin's disease. Leukemia 7:580, 1993
36. Knecht H, Bachmann E, Brousset P, Sandvej K, Nadal D, Bachmann F, Odermatt BF, Delsol G, Pallesen G: Deletions within the LMP1 oncogene of EBV are clustered in Hodgkin's disease and identical to those observed in nasopharyngeal carcinoma. Blood 82:2937,1993
37. de Campos-Lima PO, Torsteinsdottir S, Klein G, Solitzeau D, Masucci MG: Antigen processing and presentation by EBV carrying cell lines. Phenotype dependence and influence of the EBV encoded LMP1. Int J Cancer 53:856, 1993
38. Poppema S, Viser L: Absence of HLA class I expression by Reed-Sternberg cells. Am J Pathol 145:37, 1995
39. Lombardi G, Sidhu S, Batchelor R, Lechler R: Anergic T cells as suppressor cells in vitro. Science 264:1587, 1994